Company Overview and News

Grand finale of CA Sri Lanka 53rd Annual Report Awards Competition

2017-12-06 lankabusinessonline
Commercial Bank of Ceylon PLC won the coveted ‘Cyril Gardiner Memorial Trophy’ Gold Award for Overall Excellence in Annual Financial Reporting at the grand finale of the 53rd Annual Report Awards Competition organized by the Institute of Chartered Accountants of Sri Lanka (CA Sri Lanka).

MullenLowe duo win Sri Lankan leg of Young Spikes Digital Competition

Chevin Mandawala and Sagar Hiranand of MullenLowe Sri Lanka outshone their peers in the digital category at the Sri Lankan leg of Young Spikes 2016, recently. Their winning idea – Marco Knorrs it – highlighted their intimate understanding and use of digital platforms to increase the strength of Knorr and increase its usage. With this victory, the duo have won the honour of representing Sri Lanka at the Young Spikes Digital Competition to be held during the Spikes Asia Festival of Creativity in Singapore.

No. 1 Pure & Group Life Insurance Broker in Sri Lanka partners NAFILIA Congress 2016

The number one Group & Pure life insurance broker in Sri Lanka, Strategic Insurance Brokers (SIB), would be taking the 7th Congress of the National Forum for Life Insurance Advisors to a new level this year, extending the benefits of an “International Broking Partnership” for the Congress. The Congress would receive a sponsorship package that befits SIB, the undisputed leader in life insurance brokering in the country.

The 7th Annual NAFLIA Congress Attracts Over One Thousand Participants

Over one thousand life insurance sales professionals gathered at the BMICH on the 19th of August for the 7th annual National Forum for Life Insurance Advisers (NAFLIA). Organized by the Marketing and Sales Forum of the Insurance Association of Sri Lanka (IASL), the theme of the congress was “A Day All Sri Lankans Are Insured.”

Oxford College of Business CSR initiative, recognized as one of the best in Asia

Singapore was the host to the Annual Enterprise Asia, Asia Responsible Entrepreneurship Awards and International CSR Sumit 2016 on 24th June 2016 at Resort World, Resort World Sentosa, Convention Center, Singapore. Over 200 senior executives from multinational and leading corporations in Asia attended the event and witnessed the awards presentation.

John Keells Holdings 9-month net up 6-pct, 3Q net down

2016-01-29 lankabusinessonline
Jan 29, 2016 (LBO) - Sri Lanka's diversified John Keells Holdings said group net profit grew six percent in the nine months to December despite a weaker performance in transportation, leisure, info...

Delta Air Lines Inc.'s Revenue Recovery Strengthens

2016-01-06 fool
The airline just raised its fourth quarter unit revenue guidance yet again.

Finding Alpha Through Stadium Naming Rights

2016-01-06 seekingalpha
Companies are paying increasingly high sums to put their name on sports stadiums.Companies in consumer goods, energy, industrials, technology, and utilities sig

How United Continental Holdings (UAL) Stock Stands Out in a Strong Industry

2016-01-05 zacks
United Continental Holdings is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective.

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

20h - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

21h - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...